Aldosterone Synthase Inhibitors in Hard-to-Control Hypertension: A Pharmacy Practice Guide to Place in Therapy, Safety Monitoring, and Patient Care

Hypertension is the most common and most modifiable risk factor for cardiovascular disease worldwide, yet a substantial proportion of treated patients never reach their blood pressure goal. Among them sits a particularly difficult group: those whose pressure stays high despite a well-chosen, multidrug regimen. When blood pressure remains above target on optimal or best-tolerated doses of three or more agents from different classes — typically a renin–angiotensin–aldosterone system (RAAS) blocker, a calcium channel blocker, and a diuretic — the condition is termed resistant hypertension. Estimates of how often this occurs vary with the population studied and the rigour with which adherence and white-coat effect are excluded, but most registries place the figure at roughly 5 to 10 per cent of the treated hypertensive population, with some series reporting higher. These patients matter out of proportion to their numbers, because resistant disease carries a markedly elevated burden of stroke, left ventricular hypertrophy, heart failure, and chronic kidney disease. A recurring theme in this group is aldosterone. For decades the RAAS was treated as a linear cascade that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) could reliably interrupt. In practice, suppression of aldosterone by these agents is neither complete nor durable. In a meaningful fraction of patients, plasma aldosterone drifts back towards — or beyond — pretreatment levels during chronic RAAS inhibition, a phenomenon known as aldosterone breakthrough. It is distinct from aldosterone escape, the renal mechanism by which the kidney sheds excess sodium to limit volume expansion despite mineralocorticoid excess. Breakthrough is clinically unwelcome: patients in whom it develops tend to fare worse, with faster decline in renal function and heavier proteinuria. Resistant hypertension has accordingly come to be understood, in large part, as a salt-retaining, aldosterone-driven state, an interpretation supported by the well-documented response of such patients to mineralocorticoid receptor (MR) antagonists added to an existing regimen. That response has long defined the therapeutic options. Spironolactone, first marketed in the 1960s, and the more selective eplerenone act at the mineralocorticoid receptor, blocking the downstream effect of aldosterone rather than its production. They are effective, but their use is constrained — spironolactone in particular by off-target binding at androgen and progesterone receptors, which produces gynaecomastia, breast tenderness, and menstrual disturbance, and both agents by the ever-present risk of hyperkalaemia⁴. What had been missing was a way to reduce the hormone at its source.

Aldosterone synthase inhibitors (ASIs) supply exactly that. By selectively inhibiting CYP11B2, the enzyme responsible for the final step of aldosterone biosynthesis in the adrenal zona glomerulosa, these agents lower circulating aldosterone directly. The pharmacological challenge — distinguishing CYP11B2 from its near-identical paralogue CYP11B1, which governs cortisol synthesis — frustrated earlier candidates for years. Its resolution has now produced the first genuinely new antihypertensive mechanism to reach approval in roughly two decades, an event of real significance for a therapeutic area that had seen little innovation^1,2. With approval, however, comes a practical question that the trial literature has not yet addressed for the people who will help deliver these drugs at the bedside and the counter: where do ASIs belong in the treatment pathway, and what new responsibilities do they create? This review approaches the class from a pharmacy practice perspective. It sets out the biological rationale for inhibiting aldosterone synthesis, summarises the pivotal clinical evidence, and locates these agents within current treatment algorithms as add-on therapy for uncontrolled and resistant disease. Its particular focus is the work that falls to the pharmacist — structured monitoring for hyperkalaemia, hyponatraemia, and changes in renal function; recognition of clinically relevant drug interactions; individualised care in chronic kidney disease, diabetes, and older age; and the counselling that underpins safe titration and sustained adherence. The aim is to translate a fast-moving evidence base into guidance that supports the safe and rational introduction of aldosterone synthase inhibitors into everyday hypertension care.

The Aldosterone Pathway and The Rationale for Synthase Inhibition

To understand why aldosterone synthase inhibitors, behave differently from the drugs that preceded them, it helps to begin with the hormone itself. Aldosterone is the final product of a steroidogenic pathway in the adrenal cortex. Within the zona glomerulosa, the enzyme aldosterone synthase — cytochrome P450 11B2, encoded by the gene CYP11B2 — catalyses the last three rate-limiting oxidation steps of the cascade, converting 11-deoxycorticosterone through corticosterone and 18-hydroxycorticosterone to aldosterone. Once secreted, aldosterone acts on the mineralocorticoid receptor in the distal nephron and elsewhere, promoting sodium and water retention, potassium excretion, and, over time, the vascular and renal fibrosis that accompanies chronic mineralocorticoid excess. In the salt-retaining, aldosterone-driven state that characterises much of resistant hypertension, this pathway is doing more work than it should. There are two ways to interrupt it. The established approach blocks the receptor: mineralocorticoid receptor antagonists such as spironolactone and eplerenone prevent aldosterone from binding its target, leaving the hormone in circulation but unable to act. The newer approach blocks production: aldosterone synthase inhibitors competitively inhibit CYP11B2, so that less aldosterone is made in the first place. The distinction is more than mechanistic tidiness. Because receptor blockade leaves the upstream signal intact, it tends to provoke a compensatory rise in circulating aldosterone, whereas inhibiting synthesis lowers the hormone at its source and addresses both the receptor-mediated and the receptor-independent consequences of aldosterone excess. In principle, suppressing production also blunts the aldosterone breakthrough that limits RAAS blockade, since there is simply less hormone available to break through. The reason this strategy took decades to realise lies in a quirk of adrenal biochemistry. Aldosterone synthase has a near-twin. Cortisol, the body’s principal glucocorticoid and an indispensable part of the stress response, is synthesised by 11β-hydroxylase — CYP11B1 — an enzyme that shares roughly 93 per cent of its amino-acid sequence with CYP11B2 and is most alike in precisely the heme-proximal region where a drug must bind to do its work. A molecule that inhibits one will, unless carefully designed, inhibit the other. Early agents foundered on exactly this problem: osilodrostat, the first aldosterone synthase inhibitor to reach the clinic, also suppressed cortisol, and that off-target effect confined it to the treatment of cortisol-excess states such as Cushing’s syndrome rather than hypertension. The current generation of agents was engineered specifically to escape this trap. Baxdrostat, built on a tetrahydroisoquinoline scaffold, exploits a small structural difference between the two enzymes to achieve a selectivity ratio of at least 100 to 1 for aldosterone synthase over 11β-hydroxylase. The practical consequence, confirmed across early-phase studies, is that the drug lowers plasma aldosterone in a dose-dependent fashion while leaving cortisol synthesis untouched — the long-sought proof that selective inhibition of aldosterone production is achievable in humans⁵. Its pharmacokinetics suit chronic therapy: oral bioavailability and a plasma half-life of around thirty hours allow once-daily dosing. Lorundrostat, the next agent to advance, was developed against the same selectivity benchmark and shares the essential mechanism. This selectivity is not merely an elegant chemical achievement; it defines the clinical safety conversation that follows. Because cortisol synthesis is preserved, the adrenal-insufficiency risk that doomed the first-generation inhibitors does not materialise, and trial programmes have nonetheless retained morning cortisol and adrenocorticotropic hormone stimulation testing as safety checks precisely to confirm that CYP11B1 remains spared. What the mechanism does not eliminate is the predictable consequence of lowering aldosterone itself — namely, a tendency towards potassium retention and sodium loss. That trade-off, rather than any cortisol concern, is where the pharmacist’s monitoring attention will rightly concentrate, and it is the subject of later sections.

The Evidence Base

The clinical case for aldosterone synthase inhibitors has been built across a tightly linked sequence of trials, and reading them in order makes the strength — and the present limits — of the evidence clear. The proof-of-concept came from BrigHTN, a multicentre, randomised, double-blind, placebo-controlled, dose-ranging phase 2 trial of baxdrostat in patients with treatment-resistant hypertension. Participants were already taking stable doses of at least three antihypertensive agents, one of them a diuretic, and still had a mean seated blood pressure of at least 130/80 mmHg. After twelve weeks, the difference in systolic reduction between the 2 mg group and placebo was 11.0 mmHg, and between the 1 mg group and placebo 8.1 mmHg, both statistically significant⁵. The result drew attention because reductions of that magnitude, placebo-adjusted, are uncommon in a population already on multiple drugs; the senior investigator noted that few prior antihypertensive trials had produced double-digit placebo-controlled systolic declines. Reassuringly, no serious adverse event was attributed to the drug and there were no cases of adrenocortical insufficiency, confirming in patients what the selectivity data had promised. A note of caution arrived soon after from a second phase 2 study, HALO, in which blood pressure fell almost as much in the placebo arm — a reminder that improved adherence to background therapy during a trial can blunt apparent drug effect, and that resistant hypertension is partly a problem of adherence. The pivotal evidence is BaxHTN, a phase 3 trial of 796 patients with uncontrolled or resistant hypertension, randomised to baxdrostat 1 mg, 2 mg, or placebo on top of standard care. At twelve weeks the placebo-adjusted reduction in seated systolic pressure was 9.8 mmHg for the 2 mg dose and 8.7 mmHg for the 1 mg dose, with the trial meeting its primary and all secondary endpoints, and roughly four in ten patients reaching a systolic pressure below 130 mmHg⁶. A randomised-withdrawal phase showed that blood pressure rose only modestly when the drug was stopped, suggesting a degree of durability. Bax24 then added a piece the office-based trials could not provide: using 24-hour ambulatory monitoring in resistant patients, it found a placebo-adjusted reduction in 24-hour average systolic pressure of 14.0 mmHg, with the effect sustained through the early-morning hours when cardiovascular risk peaks⁷. Together these formed the basis for regulatory approval. The case does not rest on baxdrostat alone. Lorundrostat, a second selective inhibitor, has produced concordant results. In the phase 2b Advance-HTN trial, ambulatory 24-hour systolic pressure fell by 15.4 mmHg on a stable 50 mg dose against 7.4 mmHg on placebo⁸. The larger phase 3 Launch-HTN trial, enrolling over a thousand patients across thirteen countries, met its primary endpoint with a 9.1 mmHg placebo-adjusted reduction in automated office systolic pressure at six weeks, and the drug was associated with a low incidence of hyperkalaemia⁹. An earlier dose-ranging study, Target-HTN, had already established lorundrostat’s antihypertensive signal in patients with low-renin hypertension¹⁰. That two independently developed agents lower blood pressure to a similar degree, by the same mechanism, in overlapping populations is the strongest argument that this is a genuine class effect rather than a single-molecule success.

Two honest qualifications belong here, and stating them strengthens rather than weakens the case. First, the trials are short — twelve weeks for the primary endpoints — and approval rests on blood-pressure lowering as a surrogate marker. No trial has yet reported hard cardiovascular outcomes such as stroke, myocardial infarction, or death for this class; the inference that a 9 to 10 mmHg systolic reduction will translate into fewer events is well grounded in decades of antihypertensive epidemiology but remains, for these specific drugs, an inference. Second, the populations were enriched and carefully screened, typically excluding advanced renal impairment, so real-world performance and safety will need post-marketing confirmation. These are not reasons for hesitation so much as the precise points at which pharmacist vigilance becomes valuable.

Table 1: Pivotal Clinical Trials of Aldosterone Synthase Inhibitors in Uncontrolled and Resistant Hypertension

SBP, systolic blood pressure; ABPM, ambulatory blood pressure monitoring; SAE, serious adverse event; HTN, hypertension. Placebo-adjusted values are the between-group differences reported at the stated time point.

Place In Therapy

A new mechanism is only useful to a prescriber if it has a defined place in the sequence of care, and the 2025 AHA/ACC hypertension guideline provides the scaffolding into which aldosterone synthase inhibitors must fit. The guideline reaffirms a universal treatment goal of below 130/80 mmHg, with therapy guided by blood-pressure severity, comorbidity, and estimated cardiovascular risk³. For most patients the foundation is unchanged: lifestyle measures for all, single-agent therapy for milder disease, and early two-drug combination — preferably as a single pill — for stage 2 hypertension, typically pairing a renin–angiotensin system blocker with a calcium channel blocker or a thiazide-like diuretic. The relevant territory for the new class lies further along, where blood pressure stays above goal despite a well-constructed regimen. The guideline defines this carefully. Resistant hypertension is uncontrolled pressure despite optimal doses of three first-line agents — an ACE inhibitor or ARB, a calcium channel blocker, and a thiazide-like diuretic, the guideline specifically naming chlorthalidone or indapamide — in a patient with reasonably preserved renal function³. Before any drug is added, the guideline is emphatic that the prescriber should confirm the diagnosis: review adherence, exclude white-coat effect with out-of-office readings, and search for secondary causes and interfering substances. This step matters for pharmacists in particular, because medication review and adherence assessment are core pharmacy functions, and because the HALO trial showed how easily apparent resistance dissolves once adherence improves. A patient mislabelled as resistant does not need a fourth drug; they need the three they already have, taken properly. When true resistance is established, the guideline’s recommended fourth-line agent is a mineralocorticoid receptor antagonist — spironolactone or eplerenone — a position underpinned by the PATHWAY-2 trial and carrying a strong recommendation⁴. Where an MR antagonist cannot be tolerated or is contraindicated, the guideline lists alternatives: amiloride, a beta-blocker, an alpha-blocker, or a central sympatholytic, among others. It is into precisely this fourth-line, aldosterone-targeting niche that aldosterone synthase inhibitors arrive. They were studied as add-on therapy in patients already on two to three or more agents including a diuretic — the same population the guideline addresses — and they act on the same pathophysiological target as the MR antagonists, but one step upstream. This positioning carries an important caveat about timing. The 2025 guideline was finalised before baxdrostat’s approval, so it does not yet name aldosterone synthase inhibitors in its algorithm; the MR antagonist remains the formally recommended fourth agent. In practical terms, then, these drugs are best understood at present as an alternative aldosterone-directed option for the resistant patient who cannot tolerate spironolactone or eplerenone — most often because of spironolactone’s anti-androgenic effects such as gynaecomastia and breast tenderness — or in whom an MR antagonist has given an insufficient response. Until guideline committees formally incorporate the class and head-to-head data against spironolactone mature, framing them as a first-choice fourth agent would outrun the evidence. The honest position is that they expand, rather than replace, the aldosterone-targeting options at this step. Candidate identification therefore becomes a practical exercise the pharmacist is well placed to support. The patient who stands to benefit is one with genuinely resistant or uncontrolled hypertension, confirmed adherence, a diuretic already on board, an estimated glomerular filtration rate above roughly 45 mL/min/1.73 m² in keeping with the trial entry criteria, and a baseline potassium that leaves headroom for the predictable rise these drugs produce. Recognising this profile — and, equally, recognising the patient who is not yet a candidate because adherence or diagnosis is unsettled — is where pharmacist input adds the most value at the point of selection. The safety obligations that follow once the drug is started are the subject of the next section.

safety monitoring: the pharmacist’s core role

If the efficacy story belongs to the cardiologist, the safety story belongs substantially to the pharmacist, and it follows directly from the mechanism. A drug that lowers aldosterone will, by design, reduce the renal excretion of potassium and promote the loss of sodium. The two predictable consequences — hyperkalaemia and hyponatraemia — are not idiosyncratic surprises but the expected pharmacology of the class, which is precisely why they can be anticipated, monitored, and managed rather than simply feared. A third effect, a modest fall in estimated glomerular filtration rate, completes the trio of laboratory parameters that structure the monitoring plan. The most clinically important of these is hyperkalaemia. In the pooled, placebo-controlled trials underlying baxdrostat’s approval, hyperkalaemia was the most frequently reported adverse reaction, occurring in 6.6 per cent of patients at the 1 mg dose and 10.2 per cent at the 2 mg dose¹. Most of these elevations were modest; clinically significant rises were less common, with potassium exceeding 6.0 mmol/L in roughly 2.3 per cent of patients on 1 mg and 3.0 per cent on 2 mg in the phase 3 experience, against 0.4 per cent on placebo⁶. Reassuringly, the BrigHTN experience showed that such elevations were generally manageable: where potassium reached 6.0 mmol/L the protocol mandated temporary withdrawal, and patients who restarted the drug after a brief interruption typically completed treatment with normal potassium⁵. The lesson for practice is that hyperkalaemia with this class is usually a signal to pause and recheck, not necessarily to abandon therapy. Hyponatraemia is the second monitored effect. A serum sodium below 130 mEq/L was reported in 3.7 per cent of patients on 2 mg and 3.3 per cent on 1 mg, compared with 0.9 per cent on placebo⁶. The label accordingly advises assessing serum sodium before starting, correcting any abnormality first, and monitoring periodically thereafter, with closer attention for patients who begin with low-normal sodium or carry other risk factors for hyponatraemia¹. The third parameter, renal function, behaves in a characteristic and largely reassuring way. A decrease in mean eGFR appears early — a placebo-corrected fall of about 8.0 mL/min/1.73 m² at the 2 mg dose by week 12 — but it plateaus and then reverses after the drug is stopped, a pattern consistent with a haemodynamic rather than a structural effect on the kidney. Recognising this prevents an unnecessary discontinuation: a small, stable creatinine rise after initiation is expected, not a sign of injury. Translating this pharmacology into a concrete monitoring schedule is where the pharmacist adds the most tangible value, and the approved labelling supplies the framework¹. Potassium and sodium should be assessed and any abnormality corrected before the first dose, with potassium rechecked early and then periodically through treatment; the trials performed laboratory checks at baseline, at one to two weeks, and at four weeks, a cadence that maps neatly onto pharmacist-led review. Certain patients warrant more frequent monitoring: those aged 65 or older, those with diabetes or chronic kidney disease, and those taking other agents that raise potassium. The drug should not be initiated in patients whose baseline potassium is already high — practical thresholds in the literature suggest withholding above roughly 5.5 mmol/L — nor in those with an eGFR below 45 mL/min/1.73 m², a population in which efficacy and safety were not established. Table 2 consolidates this into a usable monitoring plan. A final point of practical judgement concerns what to do when a value drifts. The labelling’s logic is graduated rather than absolute: treat the abnormality, consider interrupting or discontinuing the drug, monitor more closely if it is restarted, and discontinue permanently only if a clinically significant disturbance recurs. This is a workflow a pharmacist can own end to end — flagging the at-risk patient before initiation, ensuring the baseline bloods are drawn, scheduling the follow-up checks, interpreting the results against these thresholds, and communicating a clear recommendation to the prescriber. It is unglamorous work, and it is exactly the work that determines whether a first-in-class drug is used safely in the months after launch.

Table 2: Practical Laboratory Monitoring Plan for Aldosterone Synthase Inhibitor Therapy